Kashi Clinical Laboratories, LLC

Kashi Clinical Laboratories, LLC was paid $5.03M by Medicaid between Jan 2018 and Dec 2024, across 52 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 37% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Oregon

Rank by total paid#9 of 46

Median peer was paid$50K

This provider vs. median101×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	6,470	$907K
2019	19,449	$1.41M
2020	21,341	$423K
2021	37,885	$407K
2022	71,249	$705K
2023	60,475	$690K
2024incomplete	38,224	$486K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	37%	31,459	14,284	$1.87M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	16%	5,852	1,729	$794K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	16%	7,824	2,906	$792K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	8.8%	50,747	11,945	$443K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	7.0%	8,956	4,362	$354K
0087U		5.5%	584	530	$278K
H0048	Alcohol and/or other drug testing: collection and handling only, specimens other than blood	5.1%	22,384	9,291	$254K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.9%	32,086	7,414	$93K
36415	Collection of venous blood by venipuncture	<1%	19,312	12,024	$22K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	4,895	1,061	$17K
80053	Comprehensive metabolic panel	<1%	7,295	5,479	$12K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	8,681	6,113	$11K

40 more codes

G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	742	$9K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	1,288	$9K
84443	Thyroid stimulating hormone (TSH)	<1%	3,453	$8K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	1,579	$7K
83036	Hemoglobin; glycosylated (A1C)	<1%	4,223	$7K
80048	Basic metabolic panel (calcium, ionized)	<1%	4,762	$6K
80061	Lipid panel	<1%	2,668	$6K
0088U		<1%	59	$5K
83880		<1%	775	$4K
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	19,100	$3K
82607		<1%	1,011	$2K
85027		<1%	1,793	$2K
82728		<1%	780	$1K
87088		<1%	1,331	$1K
87086	Culture, bacterial; quantitative colony count, urine	<1%	1,327	$1K
83735		<1%	1,058	$1K
82140		<1%	298	$1K
87077		<1%	905	$1K
87186		<1%	833	$1K
80164		<1%	476	$969.59
81000		<1%	1,701	$948.75
82746		<1%	445	$808.30
84439		<1%	661	$778.52
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	151	$737.66
83540		<1%	644	$736.91
86140		<1%	514	$679.89
83550		<1%	532	$629.97
85610		<1%	998	$594.26
83970		<1%	67	$239.29
80069		<1%	216	$139.84
85651		<1%	170	$126.48
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	134	$122.80
80177		<1%	30	$120.64
84153		<1%	32	$115.83
80159		<1%	13	$42.33
84100		<1%	57	$36.52
82570		<1%	35	$18.15
82043		<1%	15	$8.10
85018		<1%	25	$4.98
87634		0%	117	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMEHDIZADEH KASHI, ZAHRA (CEO & LAB DIRECTOR)